187 related articles for article (PubMed ID: 37655327)
1. An antigen self-assembled and dendritic cell-targeted nanovaccine for enhanced immunity against cancer.
Zhang Y; Jiang M; Du G; Zhong X; He C; Qin M; Hou Y; Liu R; Sun X
Acta Pharm Sin B; 2023 Aug; 13(8):3518-3534. PubMed ID: 37655327
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
3. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
4. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
5. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
6. A General Strategy toward Self-assembled Nanovaccine Based on Cationic Lentinan to Induce Potent Humoral and Cellular Immune Responses.
Yu R; Jin L; Song Z; Jiao L; Wang Z; Zhou Y; Ma Y; Guan S; Zhang Z; Wang D; Liu H; Sun Y; Zhang S; Cai T; Sun H; Qiu Y; Miao J; Liu Z
Small; 2024 Jun; ():e2402792. PubMed ID: 38940386
[TBL] [Abstract][Full Text] [Related]
7. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy.
Shi C; Jian C; Wang L; Gao C; Yang T; Fu Z; Wu T
J Nanobiotechnology; 2023 Sep; 21(1):347. PubMed ID: 37752555
[TBL] [Abstract][Full Text] [Related]
9. Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity.
Xu Y; Ma S; Zhao J; Chen H; Si X; Huang Z; Yu Z; Song W; Tang Z; Chen X
Biomaterials; 2022 May; 284():121489. PubMed ID: 35364489
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
11. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
12. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
13. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
15. A Fluorinated Supramolecular Self-Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy.
Jia S; Ji S; Zhao J; Lv Y; Wang J; Sun D; Ding D
Small Methods; 2023 May; 7(5):e2201409. PubMed ID: 36802205
[TBL] [Abstract][Full Text] [Related]
16. Polymer-Protein Nanovaccine Synthesized via Reactive Self-Assembly with Potential Application in Cancer Immunotherapy: Physicochemical and Biological Characterization In Vitro and In Vivo.
Zhang M; Chen W; Ju Y; Zhao H; Wang C
Macromol Rapid Commun; 2023 Dec; 44(23):e2300438. PubMed ID: 37708966
[TBL] [Abstract][Full Text] [Related]
17. Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy.
Dong Y; Gao J; Pei M; Wang X; Zhang C; Du Y; Jiang Y
Int J Nanomedicine; 2020; 15():2685-2697. PubMed ID: 32368049
[TBL] [Abstract][Full Text] [Related]
18. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
19. Lymph Node-Targeting Nanovaccine through Antigen-CpG Self-Assembly Potentiates Cytotoxic T Cell Activation.
Xi X; Zhang L; Lu G; Gao X; Wei W; Ma G
J Immunol Res; 2018; 2018():3714960. PubMed ID: 30018987
[TBL] [Abstract][Full Text] [Related]
20. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
